Alertex (Modafinil) is commonly used to help treat excessive sleepiness associated with specific underlying conditions.

The medication is applied in addressing pronounced symptoms related to chronic somnolence and recurrent sleep episodes, and may be part of symptomatic management for conditions such as narcolepsy, Obstructive Sleep Apnea (OSAHS), and Shift Work Sleep Disorder (SWD). It is considered relevant in clinical contexts that involve symptom patterns of sleepiness associated with a misaligned body clock or established sleep disorders. This supportive therapeutic benefit may assist with easing the overall burden associated with the sleep drive that interferes with daily functioning.

Quick Fact: Focus on Excessive Daytime Sleepiness

The medication is used for managing symptom clusters of impaired sustained vigilance by supporting the patient's capacity to maintain necessary levels of focus and wakefulness during planned periods. This key benefit may assist with easing the functional strain of chronic sleepiness, contributing to maintaining functional stability in routine activities.

Regulatory References

1. NIH MedlinePlus Drug Information

Eligibility Map: Who can and cannot use Alertex — Official Regulatory Information

Eligibility Scope	Regulatory Eligibility Statement
Populations Allowed	Adult Patients (typically age 17 or 18 and older)
Populations Contraindicated	Patients with known Hypersensitivity to modafinil or armodafinil.
	Patients with Uncontrolled Moderate to Severe Hypertension or Cardiac Arrhythmias.
	Pregnant Females and Females of reproductive potential not using effective non-hormonal contraception.
Age-Related Rules	Pediatric Use is not established; use is not recommended (under 17/18 years).
	Geriatric Patients (ge 65 years) require consideration of lower doses and close monitoring.
Condition-Specific Rules	Severe Hepatic Impairment requires a dose reduction by one-half.
	Use with Caution in Severe Renal Impairment (dosing safety/efficacy not established).
Restrictions & Limitations	Not recommended for patients with Documented Left Ventricular Hypertrophy (LVH).
	Use requires Caution in patients with a history of Psychosis, Depression, Mania, or Substance Abuse.
Pregnancy Status	Contraindicated.

---

The official eligibility profile is structured by a clear set of exclusions, permitting use primarily in the adult population who lack specific contraindications related to cardiovascular health, hypersensitivity, or reproductive status. Eligibility is restricted by conditional limitations that require caution in patients with impaired organ function or a relevant psychiatric history, as specified in regulatory documentation.

Alertex (modafinil) has the potential to interact with a significant number of other medications, supplements, and products. These interactions primarily occur because modafinil can alter the activity of certain liver enzymes responsible for drug metabolism (specifically CYP3A4, which it induces, and CYP2C19, which it weakly inhibits).

Hormonal Contraceptives

Modafinil may decrease the effectiveness of hormonal birth control methods, including oral contraceptives (pills), patches, rings, injections, and implants. Patients using hormonal contraception should discuss alternative, non-hormonal methods of birth control with their healthcare provider, and should continue using an alternative method for at least one month after stopping Alertex.

Other Significant Drug Interactions

Close monitoring or dose adjustment may be necessary if Alertex is taken with the following types of medications, as their effect in the body may be altered:

Drug Type	Potential Interaction Result
Anticonvulsants (e.g., phenytoin, phenobarbital)	May increase the concentration and side effects of the anticonvulsant.
Anticoagulants (e.g., warfarin)	May change the anticoagulant effect, requiring frequent monitoring of blood clotting time.
Certain Antidepressants/Anxiolytics (e.g., clomipramine, diazepam)	May increase the concentration of these drugs, increasing the risk of side effects.
Cyclosporine	May lower the concentration of cyclosporine, making it less effective.
Monoamine Oxidase Inhibitors (MAOIs)	Concomitant use is generally not recommended and should be avoided.

Other Products

The simultaneous consumption of high amounts of caffeine (found in coffee, tea, and energy drinks) may increase the likelihood of experiencing central nervous system stimulant effects, such as nervousness, irritability, and difficulty sleeping. Alcohol should be avoided as it may increase the risk of dizziness and impaired judgment.

The mechanism of Alertex (Modafinil) is defined by a molecular cascade that selectively increases activity within the brain's wakefulness-promoting systems.

Modulating the Dopamine Reuptake Mechanism

Alertex acts as a weak inhibitor of the Dopamine Transporter (DAT), the protein responsible for clearing dopamine from the synapse. By blocking this reuptake, the drug increases the synaptic concentration of dopamine, which initiates the subsequent activation of key arousal centers. This action results in a change in excitatory tone within the CNS arousal network.

Activating Hypothalamic Arousal Networks

The initial elevation of dopamine indirectly triggers the Orexin neurons in the hypothalamus, which are fundamental components of the system that regulates arousal. This leads to the cascade activation of Histaminergic neurons, resulting in the widespread release of histamine and other excitatory signals. This targeted engagement results in a prolonged, high-frequency output from hypothalamic arousal systems.

The Role of Enantiomeric Specificity

The drug is a racemic mixture, meaning it contains two molecular forms (R and S), where the R-enantiomer possesses a stronger binding affinity for the Dopamine Transporter. This stereochemical distinction contributes to the prolonged presence of the R-enantiomer at the target site, which results in extended engagement of the central arousal pathways.

How Alertex is Used: Official Administration Guidelines

Alertex contains Modafinil and is administered as an oral tablet. The general principle of its use is to maintain wakefulness during necessary periods, and the timing of administration is tailored to the specific condition being addressed. The standard dose for adults across the approved indications (narcolepsy, Obstructive Sleep Apnea, and Shift Work Sleep Disorder) is 200 mg taken once daily.

---

Standard Dosage and Timing

Feature	Official Label Instruction
Route & Form	Oral tablet, swallowed whole.
Standard Daily Dose	200 mg once daily.
Maximum Dose	Up to 400 mg per day, in single or divided doses.
Timing (Narcolepsy/OSA)	Taken once daily in the morning.
Timing (SWD)	Taken approximately one hour prior to the start of the work shift.
With or Without Food	May be taken with or without food.

---

Population-Specific Dosing

For patients with severe hepatic impairment, the official guidance requires the daily dose to be reduced by half, to a maximum of 100 mg. In geriatric patients (those over 65 years), a lower initial dose of 100 mg daily is advised due to potential differences in drug clearance. The medication is not typically indicated for use in pediatric patients. When used for Obstructive Sleep Apnea, Modafinil is explicitly intended as an adjunct to primary management, such as continuous positive airway pressure (CPAP), and is not a substitute for this treatment. The requirement for continued use should be subject to periodic re-evaluation by a healthcare provider.

Research evidence / Overview of Studies for Alertex

---

Evidence for Use in Narcolepsy

Research examining Alertex was studied for use in narcolepsy, primarily using short-term, placebo-controlled, double-blind Randomized Controlled Trials (RCTs). The evidence base also includes systematic reviews and meta-analyses. These studies included adult patients and compared the medicine against a non-active pill, with researchers used in research exploring how symptoms change over time. Researchers used specialized tests, such as the Maintenance of Wakefulness Test (MWT), to objectively measure outcomes reflecting daily functioning. They also used patient-reported outcomes describing perceived discomfort, like the Epworth Sleepiness Scale, to track subjective experiences.

The findings describe patterns observed in the studies, with research highlighting changes measured during the short study period in both the objective tests of wakefulness and the subjective sleepiness scores. Studies contribute to the broader evidence landscape related to short-term changes in excessive daytime sleepiness (EDS).

What remains uncertain is the long-term characterization of outcomes beyond the typical intermediate follow-up periods. Existing studies provide limited information regarding the medicine's effect on other narcolepsy symptoms, such as cataplexy.

Evidence for Use in Obstructive Sleep Apnea/Hypopnea Syndrome (OSAHS)

Alertex was studied for use in managing excessive daytime sleepiness (EDS) in adult patients with OSAHS who were already adhering to standard primary therapy, such as Continuous Positive Airway Pressure (CPAP). The research examined whether using this medicine was associated with differences in residual sleepiness that sometimes persists despite effective treatment of the underlying condition. The main study types were short-term, placebo-controlled RCTs, which monitored outcomes related to systemic or functional imbalance like the ability to maintain alertness.

Trials described patterns in residual excessive daytime sleepiness measurements in patients using standard OSAHS therapy, though a strong placebo effect was observed in some studies. The medicine was evaluated in this context only as an adjunct, meaning it does not address the underlying breathing obstruction characteristic of OSAHS.

Evidence for Use in Chronic Shift Work Sleep Disorder (SWD)

Research examining Alertex was evaluated in adults with Shift Work Sleep Disorder (SWD), a condition associated with functional limitations where symptoms may vary in intensity during their scheduled wake period. Studies explored short-term symptom changes, primarily using short-term, placebo-controlled RCTs. Researchers monitored outcomes reflecting daily functioning or activity level, including the ability to stay awake during the night shift and during the commute home.

Findings describe patterns observed in the studies related to maintaining wakefulness during the scheduled work period. Evidence is limited for long-term outcomes, as the trials typically monitored responses over defined time intervals of around 12 weeks.

Key Studies & References

1. Modafinil for excessive sleepiness associated with shift-work sleep disorder
2. Approved and investigational uses of modafinil: an evidence-based review

Common questions about Alertex (FAQ)

Q: Are there any common foods or drinks that should be avoided when using Alertex?

Official product information indicates that taking Alertex with food does not change how much of the medicine is absorbed, but it may cause the effects to be delayed by approximately one hour. Certain products should be used with caution, as official documents warn against consuming high amounts of caffeine and state that alcohol should be avoided due to the potential for increased central nervous system effects.

Q: What is the difference between Alertex and other similar sounding drug names?

According to official documents, the active ingredient in Alertex is modafinil, which is defined as a mixture of two molecular forms, the R- and S-enantiomers. A related medicine, armodafinil, consists solely of the R-enantiomer. This difference in composition is documented in the product information.

Q: Is Alertex known to interact with common over-the-counter pain relievers?

Regulatory documents describe that Alertex can change the activity of certain liver enzymes, such as CYP3A4 and CYP2C19. Because many other medicines, including over-the-counter products, are processed by these same enzymes, their levels in the body may be altered. The importance of reviewing all concurrent medications with a healthcare provider is noted in official documentation.

Q: What is the purpose of the different strengths or forms of Alertex?

Official guidelines define the recommended starting dose for adults as 200 mg once daily. Doses up to 400 mg may be used for some patients, but documentation indicates that additional clinical benefit beyond 200 mg is not systematically established. For specific patient populations, such as those with severe liver impairment, a lower starting dose of 100 mg is considered.

Q: Is there a link between Alertex and weight changes?

The official safety profile for Alertex lists anorexia, which is a medical term for loss of appetite, as a common adverse reaction observed in clinical trials. This is the primary documented link between the medicine and potential changes in eating habits.

Q: How does the effectiveness of Alertex compare to placebo in clinical trials?

Regulatory documents state that in studies, Alertex was compared against a non-active pill, or placebo. Researchers observed differences between the groups in objective measures of wakefulness, such as the Maintenance of Wakefulness Test (MWT) scores, and in patient-reported scores of sleepiness. These findings contribute to the understanding of the medicine’s use for excessive daytime sleepiness.

Q: What is the maximum duration of use for Alertex mentioned in the studies?

Studies supporting the medicine's effectiveness have typically monitored responses over short-term periods, such as 9 to 12 weeks. Official documentation indicates that the medicine's long-term efficacy has not been systematically established beyond these intervals. Official guidance states that the requirement for continued use should be subject to periodic re-evaluation by a healthcare provider.

Q: How long does it usually take to feel the effects of Alertex?

Official product information on the medicine’s processing in the body indicates that the concentration of Alertex in the bloodstream typically reaches its peak within 2 to 4 hours after the tablet is taken.

Q: Is it true that Alertex has been studied in children?

Clinical trials involving patients under the age of 18 were conducted. However, regulatory documents state that due to the increased risk of serious skin conditions and psychiatric adverse reactions observed in this population, the medicine is not recommended for use in pediatric patients.

Q: How long does Alertex stay in the system after the last use?

According to the medicine's processing profile, the effective elimination half-life of Alertex after multiple doses is approximately 15 hours. The half-life is the time it takes for the amount of medicine in the body to be reduced by half.

Q: How does the medicine in Alertex leave the body?

Official documents describe that the medicine is primarily processed, or metabolized, by the liver into inactive components. These inactive components are then eliminated from the body, primarily through the urine.

Q: Can Alertex cause a positive result on certain types of drug screening tests?

The active ingredient in Alertex and its components can be detected by specialized drug testing methods. For instance, the drug is listed as a banned substance by some international organizations that regulate competitive sports.

Q: What if I experience a side effect not listed in the main sections?

Official patient information states that suspected adverse reactions should be reported to the prescribing healthcare provider. Reporting mechanisms are also available for submission directly to the manufacturer or the national regulatory body responsible for safety monitoring.

Q: Does the body build up a tolerance to Alertex over time?

Documentation describes that a minimal or inconsistent decrease in the medicine’s minimum concentration in the bloodstream has been observed in some adults after multiple weeks of use. This minor change in how the body processes the medicine is noted in official sources but is described as having minimal clinical significance.

Q: How do official sources describe the potential for dependence with Alertex?

Official documents classify Alertex as a Schedule IV controlled substance. This classification is due to evidence showing the medicine can produce psychoactive and euphoric effects similar to other scheduled central nervous system stimulants, which may be associated with a potential for abuse or dependence.

Q: What does the term 'contraindication' mean in the context of Alertex?

A contraindication is a description of a condition or factor that serves as a reason to withhold a specific medical treatment because the potential for harm outweighs any benefit. For Alertex, contraindications are documented to include certain severe cardiovascular conditions and known hypersensitivity to the active ingredient.

Q: Is Alertex gluten-free or suitable for certain dietary restrictions?

The Alertex tablet contains the active ingredient along with several inactive ingredients, or excipients. Official product information states that the excipients include lactose monohydrate.

Q: How is the safety of Alertex monitored after it is released to the public?

The safety of the medicine after its initial release is monitored through post-marketing surveillance programs. Regulatory agencies use these programs to systematically collect and review reports of side effects and safety concerns that are submitted by patients and healthcare providers.

Q: Has Alertex been approved in countries outside of the US?

Yes, the medicine is approved and regulated by multiple governmental authorities outside of the United States. These include intergovernmental bodies, such as the European Medicines Agency (EMA), which oversees the approval and monitoring of medicines for countries in the European Economic Area.

How to Store and Dispose of Alertex (Modafinil)

Alertex is a prescription medicine that must be stored and handled according to specific regulatory requirements, particularly due to its classification as a Schedule IV controlled substance.

Storage Conditions

Alertex tablets must be stored at Controlled Room Temperature, which is officially defined as 20 C to 25 C (68 F to 77 F). Temporary temperature excursions are permitted up to 30 C (86 F). The medicine must be kept in a safe place to protect it from theft and misuse, aligning with controlled substance handling rules. As a non-negotiable safety rule, the product must be kept out of the reach of children.

Disposal Instructions

For disposal of unused or expired tablets, drug take-back programs are the preferred method as recommended by health authorities. If a take-back program is unavailable, the medicine should be mixed with an unappealing substance, such as used coffee grounds or dirt, sealed in a container or plastic bag, and then disposed of in the household trash. The medicine should not be flushed down a toilet or poured down a drain.